Ensysce Biosciences (ENSC) Interest & Investment Income (2018 - 2021)
Ensysce Biosciences (ENSC) posted quarterly Interest & Investment Income of $229.0 for Q1 2021, down 99.96% year-over-year from $639954.0 in Q1 2020, and down 99.96% quarter-over-quarter from $639954.0 in Q1 2020.
Ensysce Biosciences (ENSC) Interest & Investment Income (2018 - 2021) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Interest & Investment Income for 4 consecutive years, with $229.0 the latest figure, recorded in Q1 2021.
- In Q1 2021, Interest & Investment Income fell 99.96% year-over-year to $229.0; the TTM figure through Mar 2021 stood at $2.5 million (down 32.6% YoY), while the FY2020 annual figure was $719646.0, down 83.07% from the prior year.
- Interest & Investment Income declined to $229.0 in Q1 2021 per ENSC's latest filing, from $639954.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.2 million in Q2 2019 and bottomed at $229.0 in Q1 2021.
- Historically, Interest & Investment Income has averaged $851680.3 across 4 years, with a median of $912229.0 in 2018.
- Annual changes were most pronounced in 2019 — Interest & Investment Income surged 70.72% — and 2021, when it slumped 99.96%.
- Ensysce Biosciences' Interest & Investment Income stood at $1.1 million in 2018, then sank by 32.29% to $752347.0 in 2019, then dropped by 14.94% to $639954.0 in 2020, then plunged by 99.96% to $229.0 in 2021.
- Business Quant data shows ENSC's Interest & Investment Income at $229.0 in Q1 2021, $639954.0 in Q1 2020, and $752347.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 229.00 |
| Mar 31, 2020 | 639,954.00 |
| Dec 31, 2019 | 752,347.00 |
| Sep 30, 2019 | 1.11 Mn |
| Jun 30, 2019 | 1.21 Mn |
| Mar 31, 2019 | 1.18 Mn |
| Dec 31, 2018 | 1.11 Mn |
| Sep 30, 2018 | 969,387.00 |
| Jun 30, 2018 | 855,071.00 |
| Mar 31, 2018 | 691,167.00 |